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Long-Living Individuals (LLIs) delay aging and are less prone to chronic inflammatory
reactions. Whether a distinct monocytes and macrophages repertoire is involved
in such a characteristic remains unknown. Previous studies from our group have
shown high levels of the host defense BPI Fold Containing Family B Member 4
(BPIFB4) protein in the peripheral blood of LLIs. Moreover, a polymorphic variant of
the BPIFB4 gene associated with exceptional longevity (LAV-BPIFB4) confers protection
from cardiovascular diseases underpinned by low-grade chronic inflammation, such
as atherosclerosis. We hypothesize that BPIFB4 may influence monocytes pool and
macrophages skewing, shifting the balance toward an anti-inflammatory phenotype. We
profiled circulating monocytes in 52 LLIs (median-age 97) and 52 healthy volunteers
(median-age 55) using flow cytometry. If the frequency of total monocyte did not change,
the intermediate CD14++CD16+ monocytes counts were lower in LLIs compared to
control adults. Conversely, non-classical CD14+CD16++ monocyte counts, which are
M2macrophage precursors with an immunomodulatory function, were found significantly
associated with the LLIs’ state. In a differentiation assay, supplementation of the LLIs’
plasma enhanced the capacity of monocytes, either from LLIs or controls, to acquire
a paracrine M2 phenotype. A neutralizing antibody against the phosphorylation site
(ser 75) of BPIFB4 blunted the M2 skewing effect of the LLIs’ plasma. These data
indicate that LLIs carry a peculiar anti-inflammatory myeloid profile, which is associated
with and possibly sustained by high circulating levels of BPIFB4. Supplementation of
recombinant BPIFB4 may represent a novel means to attenuate inflammation-related
conditions typical of unhealthy aging.
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GRAPHICAL ABSTRACT | Non-classical CD14+CD16++ monocytes were found higher in LLIs compared to donors. Monocyte-derived macrophages, in presence
of BPIFB4 enriched-LLIs’ plasma, displayed a better tendency to acquire an anti-inflammatory M2 phenotype.
RESULTS AND DISCUSSION
In industrialized countries, lifespan averages 78 for males and 83
for females (1), but some exceptional individuals delay aging and
live much longer than the rest of the population. Long Living
Individuals (LLIs) represent a model of positive biology and an
exceptional resource to study and find a way to improve general
public health. Research of prolonged healthy aging could lead
to important inference on mechanisms that protect from age-
related diseases (1). In turn, emerging druggable targets may
become blockbuster treatments capable of preventing or even
overpowering unhealthy aging.
Chronic inflammation is linked with shorter life expectancy
(2) and with diseases that reduce the quality of life of elderly
people (termed inflammaging) (3). Several markers have been
proposed to track systemic and vascular inflammation (4), but
none has been developed yet to shed light on the opposite aspect
of that subject.
We posit that the peripheral blood of LLIs may hold
valuable biomarkers associated with an enduring performance
of the immune system. Circulating factors unique to LLIs
may also be directly involved in maintaining a proper balance
between M1 (pro-inflammatory) and M2 (anti-inflammatory)
macrophage phenotypes.
The bactericidal/permeability-increasing fold-containing-
family-B-member-4 (BPIFB4) is one of the most abundant
proteins in respiratory secretions, being highly concentrated
in the upper airways and proximal trachea. BPIFB4 expression
is highly responsive to airborne pathogens and participates
in host protection through antimicrobial, surfactant, and
immunomodulatory properties (5, 6). Of note, circulating
BPIFB4 levels are constitutively increased in healthy LLIs as
compared to frail ones and young controls (7). Moreover,
carriers of the longevity-associated variant (LAV) have extremely
prolonged life expectancy and show higher circulating BPIFB4
levels as compared with carrier of the wild-type haplotype (8).
Gene therapy with LAV-BPIFB4 was able to improve post-
ischemic revascularization and endothelial function (9), and to
block the atherosclerotic process in ApoE−/− mice. Moreover,
in two patient cohorts, circulating BPIFB4 levels were found
to be correlated with less carotid stenosis and intima-media
thickness (IMT) (8). The study on ApoE−/− mice also revealed
that LAV-BPIFB4 treatment determined an increased abundance
of CXCR4+Ly6Chigh precursor monocytes in bone marrow and
spleen, the two major tissue reservoirs of monocytes available
to mobilize toward injured tissues in periphery. Furthermore,
LAV-BPIFB4 overexpression conferred the animals with a
pro-resolving M2 macrophages profile. Similarly, in vitro
exposure of human monocytes from atherosclerotic patients to
the LAV-BPIFB4 recombinant protein caused a switch toward
the M2 phenotype (8).
We then hypothesize that high circulating levels of BPIFB4
associate with and are responsible for monocytes redistribution
and macrophages polarization in LLIs. To this aim, we have
studied a group of 52 LLIs (median age 97, range 95–99) from
the exceptional longevity cohort resident in Cilento, a rural area
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of Southern Italy, and compared their monocyte profile with that
of two different groups of adults (35–45 years, n= 18) and elderly
controls (65–75 years, n= 24) from the same region.
Flow-cytometry results indicate a peculiar distribution of
the monocyte pool, which uniquely marks LLIs (Figure 1).
Regarding the total circulating monocyte population, we
observed no significant variation (P < 0.05) in LLIs compared
with controls (Figure 1A). Next, subsets of monocytes were
considered (Figure 1B): CD14++CD16– classical monocytes,
CD14++CD16+ intermediate monocytes and CD14+CD16++
non-classical monocytes (Supplementary Figure 1).
Interestingly, classical monocytes did not differ between
groups (Figure 1C), whereas intermediate CD14++CD16+
monocytes were reduced (Figure 1D, P < 0.05) and non-classical
CD14+CD16++monocytes were significantly increased in LLIs
compared to young and old controls (Figure 1E, P < 0.001).
Next we confirmed LLIs have higher levels of BPIFB4 compared
with both young (35–45 years) and normally aged (65–75 years)
control groups, pointing to BPIFB4 as a bona fide biomarker
of exceptional longevity (Figure 1F). To this end, univariate
and multivariate logistic regression was applied to evaluate
the association of the variables “non-classical CD14+CD16++
monocytes” and “BPIFB4 level” on the longevity phenotype using
data from 97 subjects. As reported in Figure 1G the two variables
are independently associated with longevity, both increasing
significantly the probability of being long living individuals
when included in a multivariate model (Odds Ratio > 1, p <
0.001). Further, the percentage variation between regression
coefficients from univariate and multivariate logistic regression
was−6.24% for non-classical CD14+CD16++monocytes while
−1.46% for BPIFB4 level, thus both lower than the suggested
threshold corresponding to 10% commonly used to identify
confounders (10).
The enriched subset of non-classical monocytes is known
to actively patrol the vasculature and remove damaged cells in
several disease conditions, thereby aiding tissue healing and the
resolution of inflammation (11). Recent intravital imaging has
been crucial to definitively elucidate the molecular mechanisms
and migratory phenotype of patrolling as preeminent vascular
housekeepers (12, 13). The concept of “patrolling monocytes”
(PMo) originally referred to mouse (Ly6Clow) rather than
human cells (CD14+CD16++). However, late evidences that
differential expression patterns of certain molecules between
the 2 major subsets (classical and non-classical monocytes) are
shared in humans and mice, have contributed to strengthening
the proposed homology and the functional similarities between
species (14–16).
Circulating levels of PMo often reflect their infiltration within
the parenchyma of several tissues in most of age-related diseases,
including cancer, cardiovascular diseases, stroke, neurological
damage, arthritis. In myocardial infarction, patrolling monocytes
have been associated with reparative, proangiogenic, and pro-
arteriogenic effects (17–19). Moreover, their activity in the
clearance of amyloid beta from the brain vasculature may suggest
a protective action also in neurodegeneration (20).
To date, limited and conflicting data from mice (21) and
humans (22) indicated that monocyte subsets may change during
aging. Even if the associative nature of data does not permit
to conclude the skewed monocyte profile is relevant to the
prolonged health-span of the studied LLIs, our present work
constitutes the first study to describe a predominant monocyte
subset in people that reach extreme ages (>95 years).
Indeed an age-related trend for M2 subsets of circulating
monocytes has been partially addressed by Costantini et al.
(23). They showed that the healthy aging (>65 years) is
associated without significant changes in the frequency of the
three monocyte subsets. This is in agreement with our controls’
stratification whose analysis highlighted a significant increase of
non-classical monocytes frequency only if one compares both
younger (35–45 years) or older controls (65–75 years) with LLIs
population (>95 years). Indeed, according to Costantini, no
significant differences in patrolling frequency were reported in
older controls (65–75 years) compared to younger ones (35–45
years). Additionally, Costantini et al. also highlighted that healthy
aging is associated with an increase in CD163+ non-classical
monocytes while acute myocardial infarct (AMI) patients are
characterized by a greater frequency of non-classical CD80 M1
cells. This result even though supports the importance in disease
prevention of pro-resolving and anti-inflammatory phenotype of
monocytes, left unexplored the functional significance of age-
related monocyte phenotype changes in terms of macrophage
differentiation, that here we set out to better underpin.
We now know that, in response to an inflammatory trigger,
macrophage differentiation from circulating monocytes occurs
in tissues in concomitance with the acquisition of a functional
phenotype depending on the local environment and classified
according to their function (24).
Accumulating evidence indicates non-classical patrolling
monocytes might serve as the major precursor for tissue
resident macrophages or as precursors for alternatively activated
macrophages during inflammation (25–28). Indeed non-classical
monocytes have been seen to differentiate into protective M2-
macrophages during soft tissue injury (25). Furthermore, in a
murine model of rheumatoid arthritis non-classical monocytes
firstly differentiate into inflammatory M1-like macrophages
and then these cells polarize toward the M2-anti-inflammatory
phenotype (26). Accordingly, it makes sense that the deficiency
of NR4A1, the transcription factor that non-classical monocytes
depend upon for maturation, causes hyper-inflammatory M1-
lesional macrophages, leading to worsened atherosclerotic
plaques (27, 28).
We sought therefore to examine whether the LLIs’ plasma
could shift the phenotype of monocyte-derived macrophages
toward the pro-resolving M2 (alternatively activated) or pro-
inflammatory M1 phenotype. To this end, CD14+ monocytes
purified from blood of LLIs (range 95–99, N = 10) or
controls (35–75 years) were conditioned with autologous
plasma (added to serum-free base medium) and induced to
differentiate ex vivo into macrophages. As reported in Figure 2A,
control macrophages harvested at the end of the conditioning
period manifested an M1-M2 intermediate profile displaying
the canonical CD206+/CD163–/CD80low phenotype. On the
contrary, LLIs’ macrophages showed an enriched M2 phenotype
as highlighted by higher surface level of both CD206 and of
Frontiers in Immunology | www.frontiersin.org 3 May 2020 | Volume 11 | Article 1034
Ciaglia et al. Patrolling Monocytes Characterizing LLIs’ Blood
FIGURE 1 | Characterization of monocytic dynamics in long living individuals (LLIs). (A) Monocytes frequency in LLIs (median age 97, range 95–99, N = 52)
expressed by percentage of total CD14+ positive cells using cytofluorimetric analysis. Control group is subdivided in adults (35–45 years, n = 18) and old volunteers
(65–75 years, n = 24). (B) Representative FACS gates displaying the relative abundance of different monocyte cell subsets based on the expression of CD14+ and
CD16+ markers among freshly isolated PBMC from control volunteer (left plot, 67 years-old male) vs. LLI (right plot, 98 years-old male). (C–E) Relative abundance of
CD14++CD16– classical monocytes (green scatter plots), CD14++CD16+ intermediate monocytes (red scatter plots) and CD14+CD16++ non-classical
monocytes (deep blue scatter plots) for the different groups of controls and long living-individuals. (F) ELISA quantification of BPIFB4 levels in plasma from control
volunteers of different ages (N = 52) vs. LLIs (N = 52) expressed in mean ± SD. Pairwise comparisons statistically significant are indicated (ANOVA; *P < 0.05, ***P <
0.001). (G) Results from univariate and multivariate logistic regression. Variable, analyzed variable; Coeff (95%), 95% logistic regression coefficient and 95%
Confidence Interval; OR (95% CI), Odds Ratio and 95% Confidence Interval; p, p-value; Variation %, percentage change between univariate and multivariate
coefficients [(multivariate regression coefficient – univariate regression coefficient)/univariate regression coefficient] * 100.
the anti-inflammatory marker CD163 (Figures 2A,B). Moreover,
macrophages from LLIs secreted higher anti- (IL-10) and lower
pro-inflammatory (IL-12p70) cytokines compared to control
macrophages (Figure 2C).
Next, we asked if the favorable profile of the LLIs
plasma could be transferred in an allogenic setting,
too. Monocytes from control subjects showed a huge
increase of the percentage of CD163++ macrophages
(M2 polarizing effect) when treated with the LLIs’ plasma
(Figure 2D). On the other hand, the plasma from controls
did not influence autologous and heterologous monocytes
(Figure 2D). To be noted, donor’s plasma did not interfere
with LLI’s monocytes phenotype (Supplementary Figure 2),
suggesting that not only the functional characteristics of
LLI’s monocytes but rather the presence of peculiar soluble
factors in LLIs’ plasma may be primarily responsible for
M2 skewing.
Knock-down of BPIFB4 or mutagenesis of protein at the
functional serine 75 residue is known to abolish the BPIFB4
capacity to activate eNOS signaling and sustain endothelial
function (9). Here, we used a blocking antibody, designed on the
BPIFB4 serine 75 phosphorylation site, to verify whether, among
different soluble cytokines, BPIFB4 is responsible for the ability
of the LLIs’ plasma to promote M2 polarization of monocytes
from control subjects. Interestingly, the BPIFB4-neutralizing
antibody induced a significant decrease in macrophage M2
(CD206+/CD163+) recovery (Figures 2E,F) upon stimulation
with LLIs’ plasma.
Frontiers in Immunology | www.frontiersin.org 4 May 2020 | Volume 11 | Article 1034
Ciaglia et al. Patrolling Monocytes Characterizing LLIs’ Blood
FIGURE 2 | In vitro conditioning with plasma from long living individuals leads to polarization of LLIs and controls macrophages toward M2 phenotypes. Macrophages
were generated from peripheral blood monocytes of controls (35–75 years, N = 10) and of long living individuals (range 95–99, N = 10) upon 7 days in vitro culture
with 20% autologous plasma. (A) Panel shows FACS histogram profiles of CD206, CD163, and CD80 protein levels at the cell surface of recovered
MPL-macrophages (viable gated CD68+ cells) from a representative control volunteer (upper plots, 67 years-old male) vs. a representative LLI (lower plots, 98
years-old male). Cell staining was gated using isotype control antibodies (gray histograms). (B) Bars graph in panel report the mean fluorescence intensity (MFI) values
± SD of CD163 and CD206 M2 marker on viable CD68+ gated cells from controls (N = 10) and LLIs (N = 10). Pairwise comparisons statistically significant are
indicated (ANOVA; *P < 0.05 and **P < 0.01). (C) IL-12p70 and IL-10 secretion by control and LLIs macrophages after 1µg/ml LPS stimulation for 24 h. Cell culture
supernatants were collected and cytokines secretion was determined using bead-based multiplex ELISA. Results were expressed as the mean ± SD of all sample
determinations conducted in duplicate. All pairwise comparisons are statistically significant (ANOVA; *P < 0.05, **P < 0.01). (D–F) Peripheral blood monocytes of
control volunteers (35–75 years, N = 10) were 7 days-exposed to plasma from LLIs (N = 10) and autologous or allogenic control plasma as comparison, in the
presence or absence of BPIFB4 (1:100) blocking antibodies for the last 72 h of culture. After 7 days in vitro culture, cytofluorimetric analysis of recovered
MPL-macrophages was conducted. (D) FACS histogram profiles for CD163 M2 markers in MPL-macrophages of both control plasma- and 3 representative
LLIs-treated cells are shown. (E) Representative flow cytometry CD206 vs. CD163 density plots for each experimental condition is presented. (F) Bars graph report
the percentage ± SD of CD206+CD163+ of gated MPL-macrophages from ten independent experiments using different donors (ANOVA; **P < 0.01, ***P < 0.001).
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M2macrophages have a role in protecting frommany diseases
associated with aging. Hence, a plausible scenario emerging
from our study is that high levels of circulating BPIFB4 favor
M2 polarization thereby creating an innate immunity landscape
supportive to disease resistance and moderation of inflammatory
reactions (see cartoon). The fact that the skewing property
of the LLIs’ plasma is transferrable to controls but not vice
versa (Supplementary Figure 2) suggests the presence of factors,
including high levels of BPIFB4, endowed of immunomodulatory
therapeutic potential. Further in vivo titration studies are
necessary to determine the effective dosage and ability of




The study was performed on a group of 104 individuals: n
= 52 control volunteers (median age 55, range 35–75) and
n = 52 long-living individuals LLIs (median age 97, range
95–99). Control volunteers group was divided in middle-aged
(35–45 years) and old(er) group (65–75 years). These were
constituted, respectively, by healthy donors and by subjects
with no apparent diseases who underwent routine preventive
laboratory tests. For each, venous blood (10mL) was withdrawn
for analyses and detailed anamnesis was collected. For detailed
information concerning LLIs group see Table 1. All participants
signed an informed consent for the management of personal
anamnestic data and blood samples. The study was approved
by the IRCCS MultiMedica ethical committee and conducted
in accordance with the ethical principles deriving from the
Declaration of Helsinki.
CD14+ Monocytes Isolation and Macrophage
Generation
Peripheral Blood Mononuclear Cells (PBMC) were extracted
from whole blood by density gradient (Ficoll). After
separation, PBMC were collected and washed for the
subsequent experiments.
CD14+ monocytes were positively selected from PBMCs by
an immunomagnetic procedure (Miltenyi Biotec). Then, CD14+
cells were induced to differentiate in M1 or M2 macrophages
using reagents included in the CellXVivoTM Human M1 or M2
Macrophage Differentiation Kit (R&D system), or alternatively
in the presence of 20% human plasma (MPL). Where indicated,
plasma-stimulated monocytes were cultured in serum free base
media (R&D system) with or without BPIFB4 blocking antibody.
Blocking antibody for BPIFB4 was purchased from CliniSciences
S.r.l.-Guidonia Montecelio—Italy.
All cell cultures were conducted at 37C◦ in humidified 5%
CO2 atmosphere.
Antibodies and Flow Cytometry
Single-cell suspensions were stained with mAb against human
CD14 (HCD14; BioLegend; 1:20), CD16 (REA423; Miltenyi
Biotec GmbH; 1:50), CD206 (DCN228; Miltenyi Biotec GmbH;
TABLE 1 | Clinical Characteristic of LLIs’ group.
#Subject Gender Age (years) Major desease Drug treatments
L01 F 98 HT, DM ARBs, ASA, βB, Gl,
Metformin
L02 M 95 HT, OP ARBs ASA, ST
L03 M 95 COPD, HHD ASA, ST, Tiotropium Br
L04 F 98 DM, HHD, OP,
CV
ASA, LD, Gl, Gl
L05 F 95 HT, OP, CV ASA, ST, ACEis
L06 M 95 HT, COPD ST, ACEis, CCB,
Tiotropium Br
L07 F 95 HT, DM, OP, CV ASA, βB, Gl
L08 F 95 HT, CV ACEis
L09 M 96 HT CCB, ACEis
L10 F 96 HT, OA Indapamide
L11 F 98 HT, CV ARBs, ASA, ST, βB
L12 M 95 CV ASA
L13 M 96 COPD, HT, HF ARBs, ASA, βB, LD,
Tiotropium Br
L14 M 96 HT, DM, CV ARBs, ST, Gl, Metformin
L15 M 95 HT, HHD, CV LD, CCB
L16 F 98 HT, DM ARBs
L17 F 99 OA Nimesulide
L18 F 95 COPD, HHD CCB, Tiotropium Br
L19 F 96 HT, DM ARBs, Gl, Metformin
L20 F 100 HT ACEis
L21 F 97 HHD ARBs
L22 F 95 HT ASA
L23 F 96 HF Spironolactone,
Nitroglycerin
L24 M 96 HT LD
L25 F 95 HT βB
L26 F 99 DM, HHD LD, Metformin
L27 F 97 HT, HHD LD
L28 F 96 HHD ASA
L29 F 96 HT, HF Digoxin
L30 F 95 HT ASA, βB
L31 F 95 HT, DM ASA, βB, Metformin
L32 M 98 / /
L33 F 96 HT, COPD ASA, LD, Tiotropium Br
L34 F 95 / /
L35 F 95 HT CCB, ACEis
L36 F 98 DM Gl
L37 F 97 HT CCB
L38 F 96 HT ARBs, Indapamide
L39 F 95 HT, OP, CV ARBs
L40 M 96 HT, CV ACEis
L41 F 103 HT, DM, OP LD, Metformin
L42 F 95 DM, HHD LD, Gl
L43 F 98 OP, CV ACEis
L44 M 95 HHD CCB
L45 F 97 HT ACEis
L46 M 95 HHD, HF βB, LD
(Continued)
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TABLE 1 | Continued
#Subject Gender Age (years) Major desease Drug treatments
L47 F 97 CV Lorazepam
L48 F 98 HT, CV, DM CCB, Metformin, ACEis
L49 F 98 HT, DM ARBs, ASA
L50 M 97 HT ACEis
L51 M 96 HT, HF ASA, βB
L52 F 99 HT ST
Major disease: HT, hypertension; DM, diabetes mellitus; COPD, chronic obstructive
pulmonary disease; HHD, hypertensive heart disease; OP, osteoporosis; CV, cerebral
vasculitis; OA, osteoarthritis; HF, heart failure.
Drug treatments: ARBs, angiotensin II receptor blockers; ST, statin; ASA, acetylsalicylic
acid; βB, β beta blockers; LD, loop diuretics; ACEis, angiotensin-converting-enzyme
inhibitors; CCB, calcium channel blockers; Gl, glinides.
1:11), CD163 (REA812; Miltenyi Biotec GmbH; 1:50), CD68
(Y1/82A; BioLegend; 1:20), CD80 (2D10; BioLegend; 1:20).
After 20min incubation at 4◦C in the dark, cells were
washed and resuspended in PBS for the FACS analysis. For
each test, cells was analyzed using FACS Verse Flow Cytometer
(BD Biosciences).
Cytokines Detection
Beads-based multiplex ELISA (LEGENDplex, Biolegend, USA)
was used to measure cytokines in macrophage supernatants.
Diluted cell culture supernatants were incubated for 2 h with the
beads and detection antibodies, followed by 30min incubation
with SA-PE. After washing, beads were resuspended in washing
buffer and acquired using a FACS VERSE flow cytometer (BD
Biosciences). Data were analyzed with the LEGENDplex Data
Analysis Software.
Plasma levels of BPIFB4 were measured using
ELISA Kit (Cusabio CSB-YP003694HU) following the
manufacturer’s protocol.
Statistical Analysis
In all other experiments shown, statistical analysis was performed
by using the GraphPad prism 6.0 software for Windows
(GraphPad software). For each type of assay or phenotypic
analysis, data obtained from multiple experiments are calculated
as mean ± SD and analyzed for statistical significance using
ANOVA for multiple comparison p < 0.05 were considered
significant. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Logistic regression analyses were performed by the R software
tool (www.r-project.org).
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Supplementary Figure 1 | Gating Strategy of the three monocyte subsets based
on relative CD14 and CD16 expression. Flow cytometry dot plot showing the
gating of classical, intermediate, and non-classical monocyte subsets. From the
forward/side scatter plot monocytes were first selected. Then as by definition the
intermediate and classical monocyte subsets possess the same levels of CD14,
we found it convenient to use the end point of CD14 expression by the classical
monocytes as a set point to segregate between the intermediate and
non-classical subsets.
Supplementary Figure 2 | In vitro conditioning of LLIs’ monocytes with plasma
PL from controls. Peripheral blood monocytes of LLIs (>95 years, N = 3) were 7
days-exposed to allogenic plasma PL from control volunteers (35–75 years, N =
3) to test the inner ability of LLIs monocytes to acquire an M2 phenotype. After 7
days in vitro culture, cytofluorimetric analysis of recovered MPL-macrophages was
conducted. Bars graph report both the Mean Fluorescence Intensity and the
percentage ± SD of CD163+ (M2 marker) of gated MPL-macrophages from three
independent experiments using different donors. The skewing effects of LLIs’s
plasma (Autologous LLIs’ PL) on LLIs’s cells and autologous control plasma
(Autologous PL) on monocytes of their own (control monocytes) are also shown
for comparison (ANOVA; ∗P < 0.05).
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